{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T02:32:55Z","timestamp":1792031575098,"version":"4.4.0"},"reference-count":160,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T00:00:00Z","timestamp":1663632000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurosci."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The mainstay of therapy for many neurodegenerative dementias still relies on acetylcholinesterase inhibitors (AChEI); however, there is debate on various aspects of such treatment. A huge body of literature exists on possible predictors of response, but a comprehensive review is lacking. Therefore, our aim is to perform a systematic review of the predictors of response to AChEI in neurodegenerative dementias, providing a categorization and interpretation of the results.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a systematic review of the literature up to December 31<jats:sup>st<\/jats:sup>, 2021, searching five different databases and registers, including studies on rivastigmine, donepezil, and galantamine, with clearly defined criteria for the diagnosis of dementia and the response to AChEI therapy. Records were identified through the string:<jats:italic>predict<\/jats:italic><jats:sup>*<\/jats:sup><jats:italic>AND respon<\/jats:italic><jats:sup>*<\/jats:sup><jats:italic>AND (acetylcholinesterase inhibitors OR donepezil OR rivastigmine OR galantamine)<\/jats:italic>. The results were presented narratively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We identified 1,994 records in five different databases; after exclusion of duplicates, title and abstract screening, and full-text retrieval, 122 studies were finally included.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>The studies show high heterogeneity in duration, response definition, drug dosage, and diagnostic criteria. Response to AChEI seems associated with correlates of cholinergic deficit (hallucinations, fluctuating cognition, substantia innominate atrophy) and preserved cholinergic neurons (faster alpha on REM sleep EEG, increased anterior frontal and parietal lobe perfusion after donepezil); white matter hyperintensities in the cholinergic pathways have shown inconsistent results. The K-variant of butyrylcholinesterase may correlate with better response in late stages of disease, while the role of polymorphisms in other genes involved in the cholinergic system is controversial. Factors related to drug availability may influence response; in particular, low serum albumin (for donepezil), CYP2D6 variants associated with reduced enzymatic activity and higher drug doses are the most consistent predictors, while AChEI concentration influence on clinical outcomes is debatable. Other predictors of response include faster disease progression, lower serum cholesterol, preserved medial temporal lobes, apathy, absence of concomitant diseases, and absence of antipsychotics. Short-term response may predict subsequent cognitive response, while higher education might correlate with short-term good response (months), and long-term poor response (years). Age, gender, baseline cognitive and functional levels, and APOE relationship with treatment outcome is controversial.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fnins.2022.998224","type":"journal-article","created":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T07:46:40Z","timestamp":1663660000000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":35,"title":["Predictors of response to acetylcholinesterase inhibitors in dementia: A systematic review"],"prefix":"10.3389","volume":"16","author":[{"given":"Federico Emanuele","family":"Pozzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Conti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ildebrando","family":"Appollonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Ferrarese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucio","family":"Tremolizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.jalz.2009.04.266","article-title":"Prediction of treatment response to rivastigmine in Parkinson's disease dementia","volume":"5","author":"Adler","year":"2009","journal-title":"Alzheimers Dement"},{"key":"B2","doi-asserted-by":"publisher","first-page":"745","DOI":"10.3233\/JAD-2012-112123","article-title":"Replication study to confirm the role of CYP2D6 polymorphism rs1080985 on donepezil efficacy in Alzheimer's disease patients","volume":"30","author":"Albani","year":"2012","journal-title":"J. Alzheimers Dis"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.3390\/diagnostics11091525","article-title":"Blood-based biomarkers of neuroinflammation in Alzheimer's disease: a central role for periphery?","volume":"11","author":"Angiulli","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"B4","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13012-018-0745-6","article-title":"Impact of patient involvement on clinical practice guideline development : a parallel group study","volume":"13","author":"Armstrong","year":"2018","journal-title":"Implement. Sci."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1111\/bcp.15206","article-title":"Acute response to cholinergic challenge predicts long-term response to galantamine treatment in patients with Alzheimer's disease","volume":"88","author":"Baakman","year":"2022","journal-title":"Br. J. Clin. Pharmacol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1016\/j.neuroimage.2006.02.015","article-title":"Donepezil effects on sources of cortical rhythms in mild Alzheimer' s disease : responders vs. non-responders","volume":"31","author":"Babiloni","year":"2006","journal-title":"Neuroimage"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/j.neuron.2016.09.006","article-title":"Basal forebrain cholinergic circuits and signaling in cognition and cognitive decline","volume":"91","author":"Ballinger","year":"2017","journal-title":"Neuron"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nbd.2017.06.008","article-title":"Alzheimer's brains show inter-related changes in RNA and lipid metabolism","volume":"106","author":"Barbash","year":"2017","journal-title":"Neurobiol. Dis"},{"key":"B9","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1126\/science.7046051","article-title":"The cholinergic hypothesis of geriatric memory dysfunction","volume":"217","author":"Bartus","year":"1982","journal-title":"Science"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001190.pub3","article-title":"Donepezil for dementia due to Alzheimer's disease (Review)","author":"Birks","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"B11","doi-asserted-by":"publisher","first-page":"239","DOI":"10.3233\/JAD-160904","article-title":"Short-term response is not predictive of long-term response to acetylcholinesterase inhibitors in old age subjects with Alzheimer's disease: a \u201creal world\u201d study","volume":"56","author":"Boccardi","year":"2017","journal-title":"J. Alzheimers Dis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S0304-3940(03)00336-7","article-title":"Serum cholesterol levels modulate long-term efficacy of cholinesterase inhibitors in Alzheimer disease","volume":"343","author":"Borroni","year":"2003","journal-title":"Neurosci. Lett"},{"key":"B13","doi-asserted-by":"publisher","first-page":"664","DOI":"10.3390\/membranes11090664","article-title":"Homomeric and heteromeric \u03b17 nicotinic acetylcholine receptors in health and some central nervous system diseases","volume":"11","author":"Borroni","year":"2021","journal-title":"Membranes (Basel)"},{"key":"B14","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1177\/1533317514539540","article-title":"Effect of APOE and CHRNA7 genotypes on the cognitive response to cholinesterase inhibitor treatment at different stages of Alzheimer's disease","volume":"30","author":"Braga","year":"2015","journal-title":"Am. J. Alzheimers Dis. Other Demen"},{"key":"B15","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1007\/s00259-002-1028-6","article-title":"Acetylcholine muscarinic receptors and response to anti-cholinesterase therapy in patients with Alzheimer's disease","volume":"30","author":"Brown","year":"2003","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"B16","doi-asserted-by":"publisher","first-page":"707","DOI":"10.2165\/00002512-200825080-00007","article-title":"Defining treatment response to donepezil in Alzheimer's disease","volume":"25","author":"Burns","year":"2008","journal-title":"Drugs Aging"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e6","DOI":"10.1016\/j.archger.2008.07.006","article-title":"Efficacy of acetyl-cholinesterase-inhibitor (ACHEI) treatment in Alzheimer's disease: a 21-month follow-up \u201creal world\u201d study","volume":"49","author":"Calabria","year":"2009","journal-title":"Arch. Gerontol. Geriatr"},{"key":"B18","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12868-018-0436-x","article-title":"Higher levels of thyroxine may predict a favorable response to donepezil treatment in patients with Alzheimer disease: a prospective, case-control study","volume":"19","author":"Chang","year":"2018","journal-title":"BMC Neurosci"},{"key":"B19","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.kjms.2017.04.006","article-title":"Factors affecting therapeutic response to Rivastigmine in Alzheimer's disease patients in Taiwan","volume":"33","author":"Chen","year":"2017","journal-title":"Kaohsiung J. Med. Sci"},{"key":"B20","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1159\/000490175","article-title":"Effect of apolipoprotein E white-matter change cognitive response to acetylcholinesterase inhibitors in patients with Alzheimer's disease: a systematic review and meta-analysis","volume":"45","author":"Cheng","year":"2018","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"B21","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13195-015-0155-9","article-title":"Hippocampal atrophy but not white-matter changes predicts the long-term cognitive response to cholinesterase inhibitors in Alzheimer's disease","volume":"7","author":"Cheng","year":"2015","journal-title":"Alzheimers Res. Ther"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1007\/s00228-011-1064-x","article-title":"BCHE and CYP2D6 genetic variation in Alzheimer's disease patients treated with cholinesterase inhibitors","volume":"67","author":"Chianella","year":"2011","journal-title":"Eur. J. Clin. Pharmacol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"325","DOI":"10.3389\/fneur.2018.00325","article-title":"Suboptimal baseline serum vitamin B12 is associated with cognitive decline in people with Alzheimer's disease undergoing cholinesterase inhibitor treatment","volume":"9","author":"Cho","year":"2018","journal-title":"Front. Neurol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1159\/000124752","article-title":"Effect of ApoE genotype on response to donepezil in patients with Alzheimer's disease","volume":"25","author":"Choi","year":"2008","journal-title":"Dement. Geriatr. Cogn. Disord"},{"key":"B25","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.jfma.2021.05.026","article-title":"Impact of the CYP2D6 single nucleotide polymorphism on the concentration of and therapeutic response to donepezil in mild-to-moderate Alzheimer's disease","volume":"121","author":"Chou","year":"2021","journal-title":"J. Formos. Med. Assoc."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.3233\/JAD-160074","article-title":"CHRNA7 gene and response to cholinesterase inhibitors in an italian cohort of Alzheimer's disease patients","volume":"52","author":"Clarelli","year":"2016","journal-title":"J. Alzheimers Dis"},{"key":"B27","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12883-019-1316-4","article-title":"Peripheral vascular responses to acetylcholine as a predictive tool for response to cholinesterase inhibitors in Alzheimer's disease","volume":"19","author":"Connelly","year":"2019","journal-title":"BMC Neurol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1159\/000080964","article-title":"Current smoking and response to cholinesterase inhibitor therapy in Alzheimer's disease","volume":"19","author":"Connelly","year":"2005","journal-title":"Dement. Geriatr. Cogn. Disord"},{"key":"B29","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1002\/gps.1331","article-title":"Hypertension, white matter change and response to cholinesterase inhibitors in Alzheimer's disease","volume":"20","author":"Connelly","year":"","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"B30","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1136\/jnnp.2004.043539","article-title":"Predicting the outcome of cholinesterase inhibitor treatment in Alzheimer's disease","volume":"76","author":"Connelly","year":"","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"B31","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1002\/hup.2538","article-title":"Donepezil modulates the endogenous immune response: implications for Alzheimer's disease","volume":"31","author":"Conti","year":"2016","journal-title":"Hum. Psychopharmacol. Clin. Exp"},{"key":"B32","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1007\/s00401-014-1349-0","article-title":"Primary age-related tauopathy (PART): a common pathology associated with human aging","volume":"128","author":"Crary","year":"2014","journal-title":"Acta Neuropathol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1001\/archneur.62.11.1718","article-title":"Neuroanatomical predictors of response to donepezil therapy in patients with dementia","volume":"62","author":"Csernansky","year":"2005","journal-title":"Arch. Neurol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"913","DOI":"10.3233\/JAD-160373","article-title":"Butyrylcholinesterase K and apolipoprotein E-\u03f54 reduce the age of onset of alzheimer's disease, accelerate cognitive decline, and modulate donepezil response in mild cognitively impaired subjects","volume":"54","author":"De Beaumont","year":"2016","journal-title":"J. Alzheimers Dis"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.3233\/JAD-170497","article-title":"Change in odor identification impairment is associated with improvement with cholinesterase inhibitor treatment in mild cognitive impairment","volume":"60","author":"Devanand","year":"2017","journal-title":"J. Alzheimers Dis"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1136\/jnnp.2004.051334","article-title":"Neurophysiological predictors of long term response to AChE inhibitors in AD patients","volume":"76","author":"Di Lazzaro","year":"2005","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"B37","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1093\/sleep\/29.2.199","article-title":"The effect of donepezil on sleep and REM sleep EEG in patients with Alzheimer disease: a double-blind placebo-controlled study","volume":"29","author":"Dos Santos Moraes","year":"2006","journal-title":"Sleep"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1017\/S1041610215000289","article-title":"Initial cognitive response to cholinesterase inhibitors and subsequent long-term course in patients with mild Alzheimer's disease","volume":"27","author":"Droogsma","year":"2015","journal-title":"Int. Psychogeriatr."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1001\/jamainternmed.2021.4607","article-title":"Approval of aducanumab for Alzheimer disease \u2014 the FDA's perspective","volume":"181","author":"Dunn","year":"2021","journal-title":"JAMA Intern. Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1111\/cns.12385","article-title":"Evaluating response to high-dose 13.3 mg\/24 h rivastigmine patch in patients with severe Alzheimer's disease","volume":"21","author":"Farlow","year":"2015","journal-title":"CNS Neurosci. Ther."},{"key":"B41","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1007\/BF03401753","article-title":"Amyloid-\u03b2 induces chemokine secretion and monocyte migration across a human blood-brain barrier model","volume":"4","author":"Fiala","year":"1998","journal-title":"Mol. Med"},{"key":"B42","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1002\/pds.1345","article-title":"Identification of responders and reactive domains to rivastigmine in Alzheimer's disease","volume":"16","author":"Frankfort","year":"2007","journal-title":"Pharmacoepidemiol. Drug Saf"},{"key":"B43","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1002\/hbm.24417","article-title":"The corticotopic organization of the human basal forebrain as revealed by regionally selective functional connectivity profiles","volume":"40","author":"Fritz","year":"2018","journal-title":"Hum. Brain Mapp."},{"key":"B44","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1159\/000085069","article-title":"Do vascular lesions and related risk factors influence responsiveness to donepezil chloride in patients with Alzheimer's disease?","volume":"20","author":"Fukui","year":"2005","journal-title":"Dement. Geriatr. Cogn. Disord"},{"key":"B45","doi-asserted-by":"publisher","first-page":"495","DOI":"10.3233\/JAD-180370","article-title":"Challenges for optimizing real-world evidence in Alzheimer's disease : the ROADMAP project","volume":"67","author":"Gallacher","year":"2019","journal-title":"J. Alzheimers Dis"},{"key":"B46","doi-asserted-by":"publisher","first-page":"969","DOI":"10.3233\/JAD-150747","article-title":"Predictors of response to cholinesterase inhibitors treatment of Alzheimer's disease: date mining from the TREDEM registry","volume":"50","author":"Gallucci","year":"2016","journal-title":"J. Alzheimers Dis"},{"key":"B47","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1177\/1533317513488910","article-title":"Sensitivity and specificity of diagnostic accuracy in Alzheimer' s disease : a synthesis of existing evidence","volume":"28","author":"Gaugler","year":"2013","journal-title":"Am. J. Alzheimers Dis. Other Demen."},{"key":"B48","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1006\/geno.1998.5363","article-title":"Genomic organization and partial duplication of the human \u03b17 neuronal nicotinic acetylcholine receptor gene (CHRNA7)","volume":"52","author":"Gault","year":"1998","journal-title":"Genomics"},{"key":"B49","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1093\/brain\/awac096","article-title":"Reimagining cholinergic therapy for Alzheimer's disease","volume":"145","author":"Giacobini","year":"2022","journal-title":"Brain"},{"key":"B50","doi-asserted-by":"publisher","first-page":"2470","DOI":"10.1093\/brain\/aws173","article-title":"Imaging and acetylcholinesterase inhibitor response in dementia with Lewy bodies","volume":"135","author":"Graff-Radford","year":"2012","journal-title":"Brain"},{"key":"B51","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.jclinepi.2010.07.017","article-title":"GRADE guidelines : 4. Rating the quality of evidence d study limitations (risk of bias)","volume":"64","author":"Guyatt","year":"2011","journal-title":"J. Clin. Epidemiol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1093\/brain\/awy132","article-title":"The cholinergic system in the pathophysiology and treatment of Alzheimer's disease","volume":"141","author":"Hampel","year":"2018","journal-title":"Brain"},{"key":"B53","doi-asserted-by":"publisher","first-page":"2","DOI":"10.14283\/jpad.2018.43","article-title":"Revisiting the cholinergic hypothesis in Alzheimer's disease: emerging evidence from translational and clinical research","volume":"6","author":"Hampel","year":"2019","journal-title":"J. Prev. Alzheimers Dis"},{"key":"B54","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1159\/000068785","article-title":"Regional cerebral blood flow patterns and response to donepezil treatment in patients with Alzheimer's disease","volume":"15","author":"Hanyu","year":"2003","journal-title":"Dement. Geriatr. Cogn. Disord"},{"key":"B55","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S0304-3940(01)02507-1","article-title":"Atrophy of the substantia innominata on magnetic resonance imaging and response to donepezil treatment in Alzheimer's disease","volume":"319","author":"Hanyu","year":"2002","journal-title":"Neurosci. Lett"},{"key":"B56","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1097\/01.fpc.0000189799.88596.04","article-title":"A single nucleotide polymorphism in CHAT influences response to acetylcholinesterase inhibitors in Alzheimer's disease","volume":"16","author":"Harold","year":"2006","journal-title":"Pharmacogenet. Genomics"},{"key":"B57","doi-asserted-by":"publisher","first-page":"351","DOI":"10.3233\/JAD-160364","article-title":"Cerebral white matter changes on therapeutic response to rivastigmine in Alzheimer's disease","volume":"54","author":"Ho","year":"2016","journal-title":"J. Alzheimers Dis."},{"key":"B58","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1159\/000181148","article-title":"SPECT-identified neuroanatomical predictor of the cognitive effects of donepezil treatment in patients with Alzheimer's disease","volume":"26","author":"Hongo","year":"2008","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"B59","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1097\/JCP.0000000000001176","article-title":"Does Treatment response with antidementia drugs after 6 months in Alzheimer's disease predict long-term treatment outcome?","volume":"40","author":"Horikoshi","year":"2020","journal-title":"J. Clin. Psychopharmacol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.3390\/ijms22041593","article-title":"The role of the ATP-binding cassette A1 (ABCA1) in human disease","volume":"22","author":"Jacobo-albavera","year":"2021","journal-title":"Int. J. Mol. Sci"},{"key":"B61","doi-asserted-by":"publisher","first-page":"719","DOI":"10.2165\/00003088-200241100-00003","article-title":"Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors","volume":"41","author":"Jann","year":"2002","journal-title":"Clin. Pharmacokinet"},{"key":"B62","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1212\/01.wnl.0000228218.68451.31","article-title":"Treatment monitoring and response prediction with proton MR spectroscopy in AD","volume":"67","author":"Jessen","year":"2006","journal-title":"Neurology"},{"key":"B63","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1097\/MNM.0b013e3282f5e5f4","article-title":"Prediction of response to donepezil in Alzheimer's disease: combined MRI analysis of the substantia innominata and SPECT measurement of cerebral perfusion","volume":"29","author":"Kanetaka","year":"2008","journal-title":"Nucl. Med. Commun"},{"key":"B64","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1097\/01.wad.0000213856.89613.59","article-title":"Thyroid function in patients with Alzheimer disease: implications on response to anticholinesterase treatment","volume":"20","author":"Kapaki","year":"2006","journal-title":"Alzheimer Dis. Assoc. Disord"},{"key":"B65","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1097\/WAD.0b013e3182222bc0","article-title":"Greater responsiveness to donepezil in Alzheimer patients with higher levels of acetylcholinesterase based on attention task scores and a donepezil PET study","volume":"26","author":"Kasuya","year":"2012","journal-title":"Alzheimers Dis. Assoc. Disord"},{"key":"B66","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1159\/000330343","article-title":"Paraoxonase 1 gene polymorphisms do not influence the response to treatment in Alzheimer's disease","volume":"32","author":"Klimkowicz-Mrowiec","year":"2011","journal-title":"Dement. Geriatr. Cogn. Disord"},{"key":"B67","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/1742-2094-9-151","article-title":"Systemic immune challenges trigger and drive Alzheimer-like neuropathology in mice","volume":"9","author":"Krstic","year":"2012","journal-title":"J. Neuroinflammation"},{"key":"B68","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1159\/000111549","article-title":"Identification of responders to rivastigmine: a prospective cohort study","volume":"25","author":"Lemstra","year":"2007","journal-title":"Dement. Geriatr. Cogn. Disord"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009444.pub3","article-title":"Cholinesterase inhibitors for rarer dementias associated with neurological conditions (Review)","author":"Li","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"B70","doi-asserted-by":"publisher","first-page":"e6887","DOI":"10.7717\/peerj.6887","article-title":"Galantamine plasma concentration and cognitive response in Alzheimer's disease","volume":"7","author":"Lin","year":"2019","journal-title":"PeerJ"},{"key":"B71","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1159\/000367596","article-title":"Influence of the rs1080985 single nucleotide polymorphism of the CYP2D6 gene and APOE polymorphism on the response to donepezil treatment in patients with Alzheimer' s disease in China","volume":"4","author":"Liu","year":"2014","journal-title":"Dement. Geriatr. Cogn. Dis. Extra"},{"key":"B72","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.neulet.2015.12.062","article-title":"The roles of apolipoprotein E3 and CYP2D6 (rs1065852) gene polymorphisms in the predictability of responses to individualized therapy with donepezil in Han Chinese patients with Alzheimer's disease","volume":"614","author":"Lu","year":"2016","journal-title":"Neurosci. Lett."},{"key":"B73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.brainresbull.2018.03.014","article-title":"Association between ABCA1 gene polymorphisms and the therapeutic response to donepezil therapy in Han Chinese patients with Alzheimer's disease","volume":"140","author":"Lu","year":"2018","journal-title":"Brain Res. Bull"},{"key":"B74","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/j.jphs.2015.10.010","article-title":"CYP2D6 gene and plasma concentration of S-donepezil as biomarkers to predict and evaluate clinical outcome of donepezil in Chinese Alzheimer's disease patients","volume":"15","author":"Lu","year":"2015","journal-title":"Neurodegener. Dis"},{"key":"B75","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1177\/1533317519848237","article-title":"Effect of CYP2D6 and CYP3A4 genotypes on the efficacy of cholinesterase inhibitors in Southern Chinese patients with Alzheimer's disease","volume":"34","author":"Ma","year":"2019","journal-title":"Am. J. Alzheimers. Dis. Other Demen"},{"key":"B76","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1002\/(sici)1099-1166(199809)13:9<625::aid-gps835>3.0.co;2-2","article-title":"Effect of gender and apolipoprotein E genotype on response to anticholinesterase therapy in Alzheimer's disease","volume":"13","author":"MacGowan","year":"1998","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"B77","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s00228-010-0883-5","article-title":"Do CYP3A and ABCB1 genotypes influence the plasma concentration and clinical outcome of donepezil treatment?","volume":"67","author":"Magliulo","year":"2011","journal-title":"Eur. J. Clin. Pharmacol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"n3127","DOI":"10.1136\/bmj.n3127","article-title":"Aducanumab : European agency rejects Alzheimer's drug over efficacy and safety concerns","volume":"375","author":"Mahase","year":"2021","journal-title":"BMJ"},{"key":"B79","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1159\/000488326","article-title":"Vitamin B12 deficiency and the role of gender : a cross-sectional study of a large cohort","volume":"72","author":"Margalit","year":"2018","journal-title":"Ann. Nutr. Metab."},{"key":"B80","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jneuroim.2019.04.012","article-title":"Effect of donepezil on the expression and responsiveness to LPS of CHRNA7 and CHRFAM7A in macrophages: a possible link to the cholinergic anti-inflammatory pathway","volume":"332","author":"Maroli","year":"2019","journal-title":"J. Neuroimmunol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1016\/j.neurobiolaging.2012.12.008","article-title":"Pharmacogenomics in Alzheimer's disease: a genome-wide association study of response to cholinesterase inhibitors","volume":"34","author":"Martinelli-Boneschi","year":"2013","journal-title":"Neurobiol. Aging"},{"key":"B82","doi-asserted-by":"publisher","first-page":"108352","DOI":"10.1016\/j.neuropharm.2020.108352","article-title":"Efficacy of acetylcholinesterase inhibitors in Alzheimer's disease","volume":"190","author":"Marucci","year":"2020","journal-title":"Neuropharmacology"},{"key":"B83","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1159\/000077816","article-title":"Hallucinations predict attentional improvements with rivastigmine in dementia with lewy bodies","volume":"18","author":"McKeith","year":"2004","journal-title":"Dement. Geriatr. Cogn. Disord"},{"key":"B84","doi-asserted-by":"publisher","first-page":"199","DOI":"10.3109\/00207458708987404","article-title":"Central cholinergic systems and the P3 evoked potential","volume":"33","author":"Meador","year":"1987","journal-title":"Int. J. Neurosci"},{"key":"B85","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1046\/j.1532-5415.2002.50516.x","article-title":"Use of artificial networks in clinical trials: a pilot study to predict responsiveness to donepezil in Alzheimer's disease","volume":"50","author":"Mecocci","year":"2002","journal-title":"J. Am. Geriatr. Soc"},{"key":"B86","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1176\/jnp.12.2.209","article-title":"Orbital and dorsolateral frontal perfusion defect associated with behavioral response to cholinesterase inhibitor therapy in Alzheimer's disease","volume":"12","author":"Mega","year":"2000","journal-title":"J. Neuropsychiatry Clin. Neurosci"},{"key":"B87","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1001\/archneur.56.11.1388","article-title":"The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease","volume":"56","author":"Mega","year":"1999","journal-title":"Arch. Neurol"},{"key":"B88","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1148\/radiol.2018180092","article-title":"Altered nucleus basalis connectivity predicts treatment response in mild cognitive impairment","volume":"289","author":"Meng","year":"2018","journal-title":"Radiology"},{"key":"B89","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1159\/000435948","article-title":"Long-term response to cholinesterase inhibitor treatment is related to functional MRI response in Alzheimer's disease","volume":"40","author":"Miettinen","year":"2015","journal-title":"Dement. Geriatr. Cogn. Disord"},{"key":"B90","doi-asserted-by":"publisher","first-page":"609","DOI":"10.3233\/JAD-142148","article-title":"Predictive factors of clinical response to cholinesterase inhibitors in mild and moderate Alzheimer's disease and mixed dementia: a one-year naturalistic study","volume":"45","author":"Miranda","year":"2015","journal-title":"J. Alzheimers Dis"},{"key":"B91","doi-asserted-by":"publisher","first-page":"539","DOI":"10.3233\/JAD-160164","article-title":"Clinical response to donepezil in mild and moderate dementia: relationship to drug plasma concentration and CYP2D6 and APOE genetic polymorphisms","volume":"55","author":"Miranda","year":"2017","journal-title":"J. Alzheimers Dis"},{"key":"B92","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1177\/1533317507313675","article-title":"The clinical significance of plasmatic amyloid A\u03b2-40 peptide levels in Alzheimer's disease patients treated with galantamine","volume":"23","author":"Modrego","year":"2008","journal-title":"Am. J. Alzheimers Dis. Other Demen"},{"key":"B93","doi-asserted-by":"publisher","first-page":"253","DOI":"10.2165\/00023210-200923030-00006","article-title":"Carotid intima-media thickness as a predictor of response to cholinesterase inhibitors in Alzheimer's disease: an open-label trial","volume":"23","author":"Modrego","year":"2009","journal-title":"CNS Drugs"},{"key":"B94","doi-asserted-by":"publisher","first-page":"e0141136","DOI":"10.1371\/journal.pone.0141136","article-title":"Dysfunctional presynaptic M2 receptors in the presence of chronically high acetylcholine levels: data from the PRiMA knockout mouse","volume":"10","author":"Mohr","year":"2015","journal-title":"PLoS ONE"},{"key":"B95","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13195-014-0088-8","article-title":"Responder analysis of a randomized comparison of the 13.3 mg\/24 h and 9.5 mg\/24 h rivastigmine patch","volume":"7","author":"Molinuevo","year":"2015","journal-title":"Alzheimers Res. Ther."},{"key":"B96","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1159\/000447586","article-title":"Pretreatment cognitive profile likely to benefit from donepezil treatment in dementia with lewy bodies: pooled analyses of two randomized controlled trials","volume":"42","author":"Mori","year":"2016","journal-title":"Dement. Geriatr. Cogn. Disord"},{"key":"B97","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.archger.2004.04.040","article-title":"Effectiveness and safety of cholinesterase inhibitors in elderly subjects with Alzheimer's disease: a \u201creal world\u201d study","volume":"9","author":"Mossello","year":"2004","journal-title":"Arch. Gerontol. Geriatr. Suppl"},{"key":"B98","doi-asserted-by":"publisher","first-page":"e12158","DOI":"10.1002\/dad2.12158","article-title":"Odor identification impairment and cholinesterase inhibitor treatment in Alzheimer's disease","volume":"13","author":"Motter","year":"2021","journal-title":"Alzheimers Dement"},{"key":"B99","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1093\/brain\/awz099","article-title":"Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report","volume":"142","author":"Nelson","year":"2019","journal-title":"Brain"},{"key":"B100","article-title":"Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer's Disease.","year":"2011"},{"key":"B101","doi-asserted-by":"publisher","first-page":"110","DOI":"10.2174\/15672050113106660167","article-title":"The prediction of response to galantamine treatment in patients with mild to moderate Alzheimer's disease","volume":"11","author":"Ohnishi","year":"2014","journal-title":"Curr. Alzheimer Res."},{"key":"B102","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1097\/00002826-200309000-00008","article-title":"The effects of a cholinesterase inhibitor are prominent in patients with fluctuating cognition: a part 3 study of the main mechanism of cholinesterase inhibitors in dementia","volume":"26","author":"Onofrj","year":"2003","journal-title":"Clin. Neuropharmacol"},{"key":"B103","doi-asserted-by":"publisher","first-page":"3251","DOI":"10.2147\/DDDT.S247259","article-title":"Therapeutic drug monitoring of rivastigmine and donepezil under consideration of CYP2D6 genotype-dependent metabolism of donepezil","volume":"14","author":"Ortner","year":"2020","journal-title":"Drug Des. Dev. Ther."},{"key":"B104","doi-asserted-by":"publisher","first-page":"540348","DOI":"10.1155\/2015\/540348","article-title":"Normal hearing ability but impaired auditory selective attention associated with prediction of response to donepezil in patients with Alzheimer's disease","volume":"2015","author":"Ouchi","year":"2015","journal-title":"Behav. Neurol"},{"key":"B105","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews systematic reviews and meta-analyses","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B106","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1002\/gps.928","article-title":"Clinical predictors of response to acetyl cholinesterase inhibitors: experience from routine clinical use in Newcastle","volume":"18","author":"Pakrasi","year":"2003","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"B107","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/alzrt53","article-title":"A Quick Test of cognitive speed is sensitive in detecting early treatment response in Alzheimer disease","volume":"2","author":"Palmqvist","year":"2010","journal-title":"Alzheimers. Res. Ther"},{"key":"B108","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.2147\/CIA.S64758","article-title":"FOXO1 locus and acetylcholinesterase inhibitors in elderly patients with Alzheimer's disease","volume":"9","author":"Paroni","year":"2014","journal-title":"Clin. Interv. Aging"},{"key":"B109","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/tpj.2010.61","article-title":"Effect of apolipoprotein e and butyrylcholinesterase genotypes on cognitive response to cholinesterase inhibitor treatment at different stages of Alzheimer's disease","volume":"11","author":"Patterson","year":"2011","journal-title":"Pharmacogenomics J"},{"key":"B110","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1097\/WAD.0000000000000107","article-title":"Olfactory deficits predict cognitive improvement on donepezil in patients with depression and cognitive impairment","volume":"30","author":"Pelton","year":"2016","journal-title":"Alzheimer Dis. Assoc. Disord"},{"key":"B111","doi-asserted-by":"publisher","first-page":"e109484","DOI":"10.1371\/journal.pone.0109484","article-title":"Factors associated with response to acetylcholinesterase inhibition in dementia: a cohort study from a secondary mental health care case register in london","volume":"9","author":"Perera","year":"2014","journal-title":"PLoS ONE"},{"key":"B112","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1212\/WNL.0b013e3181b6bbe3","article-title":"Effect of a cyp2d6 polymorphism on the efficacy of donepezil in patients with Alzheimer disease","volume":"73","author":"Pilotto","year":"2009","journal-title":"Neurology"},{"key":"B113","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.neulet.2005.03.027","article-title":"Responsiveness to cholinesterase inhibitors in Alzheimer's disease: a possible role for the 192 Q\/R polymorphism of the PON-1 gene","volume":"382","author":"Pola","year":"2005","journal-title":"Neurosci. Lett"},{"key":"B114","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s00228-005-0946-1","article-title":"cohort study of effectiveness of acetylcholinesterase inhibitors in Alzheimer's disease","volume":"61","author":"Raschetti","year":"2005","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B115","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.nbd.2016.12.013","article-title":"The olfactory bulb as the entry site for prion-like propagation in neurodegenerative diseases","volume":"109","author":"Rey","year":"2018","journal-title":"Neurobiol. Dis."},{"key":"B116","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1097\/00008571-200207000-00009","article-title":"Presence or absence of at least one epsilon 4 allele and gender are not predictive for the response to donepezil treatment in Alzheimer's disease","volume":"12","author":"Rigaud","year":"2002","journal-title":"Pharmacogenetics"},{"key":"B117","doi-asserted-by":"publisher","first-page":"e20190404","DOI":"10.1590\/1678-4685-gmb-2019-0404","article-title":"Influence of a genetic variant of CHAT gene over the profile of plasma soluble ChAT in Alzheimer disease","volume":"43","author":"Rocha-dias","year":"2020","journal-title":"Genet. Mol. Biol"},{"key":"B118","doi-asserted-by":"publisher","first-page":"43","DOI":"10.6026\/97320630002039","article-title":"Short term response is predictive of long term response to acetylcholinesterase inhibitors in Alzheimer's disease: a starting point to explore Bayesian approximation in clinical practice","volume":"2","author":"Rota","year":"2007","journal-title":"Bioinformation"},{"key":"B119","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/BF03324877","article-title":"Serum albumin level interferes with the effect of Donepezil in Alzheimer's disease","volume":"20","author":"Rozzini","year":"2008","journal-title":"Aging Clin. Exp. Res"},{"key":"B120","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1080\/136515001317021653","article-title":"Ventricular measurements in computed tomography of responders and non-responders to donepezil in the treatment of Alzheimer's disease","volume":"5","author":"Salib Tony Sheridan Mark Allington","year":"2001","journal-title":"Int. J. Psychiatry Clin. Pract"},{"key":"B121","unstructured":"Understanding Multiscale Entropy2018"},{"key":"B122","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.clinbiochem.2003.10.007","article-title":"Association of a salivary acetylcholinesterase with Alzheimer's disease and response to cholinesterase inhibitors","volume":"37","author":"Sayer","year":"2004","journal-title":"Clin. Biochem"},{"key":"B123","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1002\/gps.4043","article-title":"Sex and ESR1 genotype may influence the response to treatment with donepezil and rivastigmine in patients with Alzheimer's disease","volume":"29","author":"Scacchi","year":"2014","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"B124","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1002\/ajmg.b.30846","article-title":"Variability of AChE, BChE, and ChAT genes in the late-onset form of Alzheimer's disease and relationships with response to treatment with donepezil and rivastigmine","volume":"150","author":"Scacchi","year":"2009","journal-title":"Am. J. Med. Genet. B Neuropsychiatr. Genet"},{"key":"B125","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1093\/brain\/121.12.2249","article-title":"Trajectories of cholinergic pathways within the cerebral hemispheres of the human brain","volume":"121","author":"Selden","year":"1998","journal-title":"Brain"},{"key":"B126","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1097\/FPC.0b013e32833f984c","article-title":"Role of cytochrome P4502D6 functional polymorphisms in the efficacy of donepezil in patients with Alzheimer's disease","volume":"21","author":"Seripa","year":"2011","journal-title":"Pharmacogenet. Genomics"},{"key":"B127","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/0006-3223(90)90524-6","article-title":"Molecular forms of acetylcholinesterase in subcortical areas of normal and Alzheimer disease brain","volume":"27","author":"Siek","year":"1990","journal-title":"Biol. Psychiatry"},{"key":"B128","doi-asserted-by":"crossref","first-page":"131","DOI":"10.55782\/ane-2007-1640","article-title":"Plasma Abeta levels as predictors of response to rivastigmine treatment in Alzheimer's disease","volume":"67","author":"Sobow","year":"2007","journal-title":"Acta Neurobiol. Exp. (Wars)"},{"key":"B129","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3233\/JAD-160562","article-title":"Deleterious Effect of butyrylcholinesterase K-variant in donepezil treatment of mild cognitive impairment","volume":"56","author":"Sokolow","year":"2017","journal-title":"J. Alzheimers Dis"},{"key":"B130","doi-asserted-by":"publisher","first-page":"I4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"2019","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"B131","doi-asserted-by":"publisher","first-page":"631","DOI":"10.2147\/CIA.S200109","article-title":"Effect of genetic polymorphisms on Alzheimer's disease treatment outcomes: an update","volume":"14","author":"Sumirtanurdin","year":"2019","journal-title":"Clin. Interv. Aging."},{"key":"B132","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jns.2004.07.009","article-title":"Prediction of psychiatric response to donepezil in patients with mild to moderate Alzheimer's disease","volume":"225","author":"Tanaka","year":"2004","journal-title":"J. Neurol. Sci"},{"key":"B133","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1159\/000070998","article-title":"Atrophy of the substantia innominata on magnetic resonance imaging predicts response to donepezil treatment in Alzheimer's disease patients","volume":"16","author":"Tanaka","year":"2003","journal-title":"Dement. Geriatr. Cogn. Disord"},{"key":"B134","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ghir.2007.07.006","article-title":"Use of serum insulin-like growth factor-I levels to predict psychiatric non-response to donepezil in patients with Alzheimer's disease","volume":"18","author":"Tei","year":"2008","journal-title":"Growth Horm. IGF Res."},{"key":"B135","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.neuropharm.2016.02.005","article-title":"Predictors of cognitive decline and treatment response in a clinical trial on suspected prodromal Alzheimer's disease","volume":"108","author":"Teipel","year":"2016","journal-title":"Neuropharmacology"},{"key":"B136","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1007\/s11682-019-00182-9","article-title":"Early prediction of donepezil cognitive response in Alzheimer's disease by brain perfusion single photon emission tomography","volume":"13","author":"Tepmongkol","year":"2019","journal-title":"Brain Imaging Behav"},{"key":"B137","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1185\/030079906X80279","article-title":"Response to rivastigmine or donepezil in Alzheimer's patients with symptoms suggestive of concomitant Lewy body pathology","volume":"22","author":"Touchon","year":"2006","journal-title":"Curr. Med. Res. Opin."},{"key":"B138","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/nri2566","article-title":"Reflex control of immunity","volume":"9","author":"Tracey","year":"2009","journal-title":"Nat. Rev. Immunol"},{"key":"B139","doi-asserted-by":"publisher","first-page":"953868","DOI":"10.1155\/2015\/953868","article-title":"Novel application of multiscale entropy in electroencephalography to predict the efficacy of acetylcholinesterase inhibitor in Alzheimer's disease","volume":"2015","author":"Tsai","year":"2015","journal-title":"Comput. Math. Methods Med"},{"key":"B140","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.mcn.2010.08.001","article-title":"Hypercholesterolemia in rats impairs the cholinergic system and leads to memory deficits","volume":"45","author":"Ullrich","year":"2010","journal-title":"Mol. Cell. Neurosci"},{"key":"B141","doi-asserted-by":"publisher","first-page":"698","DOI":"10.4306\/pi.2017.14.5.698","article-title":"Prediction of treatment response to donepezil using automated hippocampal subfields volumes segmentation in patients with mild Alzheimer's disease","volume":"14","author":"Um","year":"2017","journal-title":"Psychiatry Investig."},{"key":"B142","doi-asserted-by":"publisher","first-page":"108020","DOI":"10.1016\/j.neuropharm.2020.108020","article-title":"Central and peripheral anti-inflammatory effects of acetylcholinesterase inhibitors","volume":"168","author":"Vaknine","year":"2020","journal-title":"Neuropharmacology"},{"key":"B143","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/S0165-5728(02)00057-7","article-title":"Expression of an \u03b17 duplicate nicotinic acetylcholine receptor-related protein in human leukocytes","volume":"126","author":"Villiger","year":"2002","journal-title":"J. Neuroimmunol"},{"key":"B144","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1159\/000082883","article-title":"Medial temporal lobe atrophy and APOE genotype do not predict cognitive improvement upon treatment with rivastigmine in Alzheimer's disease patients","volume":"19","author":"Visser","year":"2005","journal-title":"Dement. Geriatr. Cogn. Disord"},{"key":"B145","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1002\/gps.2195","article-title":"Can CSF biomarkers or pre-treatment progression rate predict response to cholinesterase inhibitor treatment in Alzheimer's disease?","volume":"24","author":"Wallin","year":"2009","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"B146","doi-asserted-by":"publisher","first-page":"905","DOI":"10.2174\/1567205015666180507105326","article-title":"Short-term response to cholinesterase inhibitors in Alzheimer's disease delays time to nursing home placement","volume":"15","author":"Wattmo","year":"2018","journal-title":"Curr. Alzheimer Res"},{"key":"B147","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13195-017-0294-2","article-title":"Early- versus late-onset Alzheimer's disease in clinical practice: cognitive and global outcomes over 3 years","volume":"9","author":"Wattmo","year":"2017","journal-title":"Alzheimers Res. Ther."},{"key":"B148","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/alzrt85","article-title":"Predictors of long-term cognitive outcome in Alzheimer's disease","volume":"3","author":"Wattmo","year":"2011","journal-title":"Alzheimers Res. Ther."},{"key":"B149","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/1471-2377-12-134","article-title":"Functional response to cholinesterase inhibitor therapy in a naturalistic Alzheimer's disease cohort","volume":"12","author":"Wattmo","year":"2012","journal-title":"BMC Neurol"},{"key":"B150","doi-asserted-by":"publisher","first-page":"e84059","DOI":"10.1371\/journal.pone.0084059","article-title":"CHRNA7 polymorphisms and response to cholinesterase inhibitors in Alzheimer's disease","volume":"8","author":"Weng","year":"2013","journal-title":"PLoS ONE"},{"key":"B151","unstructured":"Dementia2021"},{"key":"B152","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/ggi.13153","article-title":"Location of white matter changes and response to donepezil in patients with Alzheimer's disease: a retrospective and observational study","volume":"18","author":"Wu","year":"2018","journal-title":"Geriatr. Gerontol. Int."},{"key":"B153","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1007\/s40263-016-0356-1","article-title":"Effect of the CYP2D6 and APOE polymorphisms on the efficacy of donepezil in patients with Alzheimer's disease: a systematic review and meta-analysis","volume":"30","author":"Xiao","year":"2016","journal-title":"CNS Drugs"},{"key":"B154","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.regpep.2010.04.010","article-title":"Preliminary use of insulin-like growth factor-I as a biomarker for sorting high-dose donepezil responders among Japanese patients with Alzheimer's disease","volume":"163","author":"Yamagata","year":"2010","journal-title":"Regul. Pept"},{"key":"B155","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1097\/JCP.0b013e31828b5087","article-title":"Concentration of donepezil to the cognitive response in alzheimer disease","volume":"33","author":"Yang","year":"2013","journal-title":"J. Clin. Psychopharmacol"},{"key":"B156","doi-asserted-by":"publisher","first-page":"209","DOI":"10.2147\/PGPM.S211259","article-title":"Influence of CYP2D6, CYP3A5, ABCB1, APOE polymorphisms and nongenetic factors on donepezil treatment in patients with Alzheimer's disease and vascular dementia","volume":"12","author":"Yaowaluk","year":"2019","journal-title":"Pharmgenomics Pers. Med"},{"key":"B157","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1055\/s-0035-1545300","article-title":"Association of the choline acetyltransferase gene with responsiveness to acetylcholinesterase inhibitors in Alzheimer's disease","volume":"48","author":"Yoon","year":"2015","journal-title":"Pharmacopsychiatry"},{"key":"B158","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s12149-007-0022-2","article-title":"Effectiveness of treatment with donepezil hydrochloride and changes in regional cerebral blood flow in patients with Alzheimer's disease","volume":"21","author":"Yoshida","year":"2007","journal-title":"Ann. Nucl. Med"},{"key":"B159","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1097\/MAJ.0b013e318255a8f9","article-title":"Effect of CYP2D6*10 and APOE polymorphisms on the efficacy of donepezil in patients with Alzheimer's disease","volume":"345","author":"Zhong","year":"2013","journal-title":"Am. J. Med. Sci"},{"key":"B160","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.jalz.2012.09.015","article-title":"Long-term associations between cholinesterase inhibitors and memantine use and health outcomes among patients with Alzheimer' s disease","volume":"9","author":"Zhu","year":"2013","journal-title":"Alzheimers Dement"}],"container-title":["Frontiers in Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnins.2022.998224\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T04:58:50Z","timestamp":1728017930000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnins.2022.998224\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,20]]},"references-count":160,"alternative-id":["10.3389\/fnins.2022.998224"],"URL":"https:\/\/doi.org\/10.3389\/fnins.2022.998224","relation":{},"ISSN":["1662-453X"],"issn-type":[{"value":"1662-453X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,20]]},"article-number":"998224"}}